On March 19, 2026, CervoMed Inc. announced new analyses from its Phase 2b RewinD-LB clinical trial targeting dementia with Lewy bodies, to be presented at a conference in Copenhagen on March 21, 2026. This event is significant for investors as it pertains to the company's ongoing research and trials.